Business
Half Yearly Report
Half Yearly Report.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 9355S Immupharma PLC 30 September 2014 \n\n\n\n\n\n \n\n\n30 SEPTEMBER 2014\n\n\n\n\n \nImmuPharma\n \nINTERIM RESULTS ANNOUNCEMENT\nfor the six months ended 30 June 2014\n \nImmuPharma PLC (LSE:IMM), (\"ImmuPharma\" or the \"Company\"), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2014.\n \nKey Highlights:\n \n· LupuzorTM\no Announced separately today - Phase III activities of lead compound LupuzorTM will soon commence: Following advanced discussions and after completing detailed due diligence with a potential partner, ImmuPharma has started the preparatory steps for LupuzorTM's pivotal phase III clinical trials. Before these initial activities are completed, it is expected that a further agreement to develop LupuzorTM will be finalised and signed which will see ImmuPharma and the potential partner fund the phase III trials. This agreement will also allow the partner to run the phase III pivotal programme based on the strengthened study protocol agreed between ImmuPharma and the FDA.\no Positive amendment to SPA for Lupuzor Phase III trial in place\no £50M equity finance facility secured from Henderson Global's subsidiary Darwin Strategic to assist with Phase III trial funding\n \n· Scientific Advisory Board comprising worldwide key opinion leaders in lupus in place to guide Phase III clinical development\n \n· Nucant cancer programme IPP-204106\no Phase I/IIa clinical trial with the next generation \"polyplexed Nucant\" formulation in three European hospitals including the prestigious Institute Jules Bordet in Belgium has recently been completed. \no Trial results and next steps to be announced in the near future.\no Patents granted surrounding an \"optically pure\" version of the Nucant family.\n \n· In collaboration with the CNRS, access to pioneering research around novel peptide drugs through the University of Bordeaux and the research team incubator, Institut Europeen de Chimie et Biologie (IECB).\n \n· Key events:\n \no ImmuPharma...